
|Videos|November 17, 2018
Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia
Author(s)Abhinav Deol, MD
Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.
Advertisement
Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5



































